U.S. pharma large copyright scrapped two experimental weight loss supplements past year—a at the time-everyday capsule, lotiglipron, as a consequence of elevated liver enzymes as well as a twice-each day tablet, danuglipron, resulting from robust side effects—but CEO Albert Bourla has said the company is set to “play and acquire” in the obe